AKTX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 7.83%, SMA50 -0.7%, SMA200 -65.85%). The stock’s 14-day RSI is 52.28 (neutral), while the ATR of 0.03 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -85.02% below its high and over 19.01% above its low. Average 10-day trading volume of 51.60 thousand shares is below the 3-month average of 713.17 thousand, indicating normal recent market interest.

Akari Therapeutics, Plc has 1.75 million shares outstanding. The public float is 704.67 thousand shares, elevated short interest at 1.96% of float. This equals 18.00 thousand shares. The short ratio is 0.17 days. Institutional investors hold 11.29% of the float. Insiders own 16.8%. Cohen Mark S holds 1.06 million shares, SABBY MANAGEMENT, LLC has 778.03 thousand shares and Huh Hoyoung has 618.66 thousand shares.

Wall Street analysts project EPS growth of 46.44% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $1.00. The high target offers 222.93% upside. The low target suggests -89.24% downside. The mean target is $14.90. This offers 60.39% upside. Akari Therapeutics, Plc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 19, 2026, missed forecasts by 51629.32%. The prior quarter beat by 66.11%. Over the last six quarters, Apple has recorded several small beats. These include 33.33% in September 25, 2025.

Akari Therapeutics, Plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.29. This means the shares are trading above this model’s fair value.

Akari Therapeutics, Plc (NASDAQ:AKTX) closed at $9.29 USD, losing -$1.37 (-12.80%) from the previous close of $10.66. The stock is currently mid-range between its 52-week high and low $3.02 and $49.60. With a market capitalization of about $10.64 million, Akari Therapeutics, Plc is classified as a micro-cap and shows higher-than-market volatility (beta ~1.39). Key stats such as the average daily volume over the past year has been around 793.92 thousand shares, volume is running light vs its 52-week average. Headquartered in Tampa, FL, Akari Therapeutics, Plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Abizer Gaslightwala, the company employs approximately 6 people and listed since January 06, 2014. Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins.

Akari Therapeutics, Plc trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.01 suggesting the stock is closer to book value. The P/FCF stands at -1.02, also above market averages.

Our AI price prediction model suggests that Akari Therapeutics, Plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.08%, with price expected at $9.40 by August 04, 2026, within a range of $7.32 to $11.60 3-Month Outlook: Projected rise of 44.95%, reaching $13.48 by October 19, 2026, with a range of $11.89 to $14.97. 1-Year Outlook: Projected loss of -82.8%, with price at $1.60 by July 21, 2027, within a range of $0.00 to $0.00.

Akari Therapeutics, Plc (NASDAQ:AKTX) shares are flat -8.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Akari Therapeutics, Plc trading at a premium to the broader market with a P/E of -0.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.67, suggesting -17.53% downside. Our AI forecast model points to short-term strength (1.08% over two weeks), a medium-term rise (44.95% over three months), and a longer-term loss (-82.8% over one year), with expected trading ranges indicating moderate volatility.